202 related articles for article (PubMed ID: 37603060)
1. Renin-angiotensin inhibitors reduce thrombotic complications in Essential Thrombocythemia and Polycythemia Vera patients with arterial hypertension.
Mulas O; Mola B; Costa A; Pittau F; Mantovani D; Dessì S; Fronteddu A; La Nasa G; Caocci G
Ann Hematol; 2023 Oct; 102(10):2717-2723. PubMed ID: 37603060
[TBL] [Abstract][Full Text] [Related]
2. Prediction of thrombotic and hemorrhagic events during polycythemia vera or essential thrombocythemia based on leukocyte burden.
Lim Y; Lee JO; Kim SH; Kim JW; Kim YJ; Lee KW; Lee JS; Bang SM
Thromb Res; 2015 May; 135(5):846-51. PubMed ID: 25743883
[TBL] [Abstract][Full Text] [Related]
3. Statin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemia.
Podoltsev NA; Wang R; Shallis RM; Stempel JM; Di M; Neparidze N; Zeidan AM; Huntington SF; Giri S; Hull SC; Gore SD; Ma X
Cancer Med; 2023 Sep; 12(18):18889-18900. PubMed ID: 37702132
[TBL] [Abstract][Full Text] [Related]
4. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments.
De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Gerli G; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Marchioli R; Leone G; Barbui T;
Haematologica; 2008 Mar; 93(3):372-80. PubMed ID: 18268279
[TBL] [Abstract][Full Text] [Related]
5. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
[TBL] [Abstract][Full Text] [Related]
6. Thrombotic events and mortality risk in patients with newly diagnosed polycythemia vera or essential thrombocythemia.
Pemmaraju N; Gerds AT; Yu J; Parasuraman S; Shah A; Xi A; Kumar S; Scherber RM; Verstovsek S
Leuk Res; 2022 Apr; 115():106809. PubMed ID: 35220060
[TBL] [Abstract][Full Text] [Related]
7. Thrombosis among 1537 patients with JAK2
Zhang Y; Zhou Y; Wang Y; Teng G; Li D; Wang Y; Du C; Chen Y; Zhang H; Li Y; Fu L; Chen K; Bai J
Cancer Med; 2020 Mar; 9(6):2096-2105. PubMed ID: 31994332
[TBL] [Abstract][Full Text] [Related]
8. [Thrombosis in myeloproliferative neoplasms].
Asakura H
Rinsho Ketsueki; 2018; 59(8):1034-1041. PubMed ID: 30185703
[TBL] [Abstract][Full Text] [Related]
9. Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark survey.
Mesa RA; Miller CB; Thyne M; Mangan J; Goldberger S; Fazal S; Ma X; Wilson W; Paranagama DC; Dubinski DG; Naim A; Parasuraman S; Boyle J; Mascarenhas JO
Cancer; 2017 Feb; 123(3):449-458. PubMed ID: 27690182
[TBL] [Abstract][Full Text] [Related]
10. Do All Patients With Polycythemia Vera or Essential Thrombocythemia Need Cytoreduction?
Sankar K; Stein BL
J Natl Compr Canc Netw; 2018 Dec; 16(12):1539-1545. PubMed ID: 30545998
[TBL] [Abstract][Full Text] [Related]
11. Prolonged Proton Pump Inhibitor Use and Thrombohemorrhagic Risk in Essential Thrombocythemia and Polycythemia Vera Patients Treated with Long-Term Aspirin: A Pilot Study.
Krečak I; Pivac L; Holik H; Perić MM; Zekanović I; Čubrić E; Skelin M; Lucijanić M
Pharmacology; 2024; 109(2):110-114. PubMed ID: 38171342
[TBL] [Abstract][Full Text] [Related]
12. Assessing disease burden in patients with classic MPNs.
Geyer H; Mesa RA
Best Pract Res Clin Haematol; 2014 Jun; 27(2):107-19. PubMed ID: 25189722
[TBL] [Abstract][Full Text] [Related]
13. Arterial stenosis and atherothrombotic events in polycythemia vera and essential thrombocythemia.
Cucuianu A; Stoia M; Farcaş A; Dima D; Zdrenghea M; Paţiu M; Olinic D; Petrov L
Rom J Intern Med; 2006; 44(4):397-406. PubMed ID: 18386616
[TBL] [Abstract][Full Text] [Related]
14. Highly reduced survival in essential thrombocythemia and polycythemia vera patients with vascular complications during follow-up.
Ahlstrand E; Samuelsson J; Lindgren M; Pettersson H; Liljeholm M; Ravn-Landtblom A; Scheding S; Andréasson B
Eur J Haematol; 2020 Mar; 104(3):271-278. PubMed ID: 31863513
[TBL] [Abstract][Full Text] [Related]
15. Chronic kidney disease could be a risk factor for thrombosis in essential thrombocythemia and polycythemia vera.
Krečak I; Holik H; Martina MP; Zekanović I; Coha B; Gverić-Krečak V
Int J Hematol; 2020 Sep; 112(3):377-384. PubMed ID: 32514928
[TBL] [Abstract][Full Text] [Related]
16. Reduction of antithrombin III, protein C, and protein S levels and activated protein C resistance in polycythemia vera and essential thrombocythemia patients with thrombosis.
Bucalossi A; Marotta G; Bigazzi C; Galieni P; Dispensa E
Am J Hematol; 1996 May; 52(1):14-20. PubMed ID: 8638606
[TBL] [Abstract][Full Text] [Related]
17. [Risk factors for recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia].
Han X; Bai BB; Wang CJ; Zhao S; Chen Y
Zhonghua Xue Ye Xue Za Zhi; 2019 Jan; 40(1):17-23. PubMed ID: 30704223
[No Abstract] [Full Text] [Related]
18. Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients.
Mora B; Guglielmelli P; Kuykendall A; Rumi E; Maffioli M; Palandri F; De Stefano V; Caramella M; Salmoiraghi S; Kiladjian JJ; Gotlib J; Iurlo A; Cervantes F; Ruggeri M; Silver RT; Albano F; Benevolo G; Ross DM; Della Porta MG; Devos T; Rotunno G; Komrokji RS; Casetti IC; Merli M; Brociner M; Caramazza D; Auteri G; Barbui T; Cattaneo D; Bertù L; Arcaini L; Vannucchi AM; Passamonti F
Leukemia; 2022 Oct; 36(10):2453-2460. PubMed ID: 36042316
[TBL] [Abstract][Full Text] [Related]
19. Aspirin for the control of platelet activation and prevention of thrombosis in essential thrombocythemia and polycythemia vera: current insights and rationale for future studies.
Landolfi R; Di Gennaro L; Novarese L; Patrono C
Semin Thromb Hemost; 2006 Apr; 32(3):251-9. PubMed ID: 16673279
[TBL] [Abstract][Full Text] [Related]
20. Low-risk polycythemia vera and essential thrombocythemia: management considerations and future directions.
Goulart H; Mascarenhas J; Tremblay D
Ann Hematol; 2022 May; 101(5):935-951. PubMed ID: 35344066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
